RT Journal Article
SR Electronic
T1 Age acquired skewed X Chromosome Inactivation is associated with adverse health outcomes in humans
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.04.22272893
DO 10.1101/2022.04.04.22272893
A1 Roberts, Amy L.
A1 Morea, Alessandro
A1 Amar, Ariella
A1 Zito, Antonino
A1 El-Sayed Moustafa, Julia S.
A1 Tomlinson, Max
A1 Bowyer, Ruth C. E.
A1 Zhang, Xinyuan
A1 Christiansen, Colette
A1 Costeira, Ricardo
A1 Steves, Claire J.
A1 Mangino, Massimo
A1 Bell, Jordana T.
A1 Wong, Chloe C.Y.
A1 Vyse, Timothy J.
A1 Small, Kerrin S.
YR 2022
UL http://medrxiv.org/content/early/2022/04/05/2022.04.04.22272893.abstract
AB Background Ageing is a heterogenous process characterised by cellular and molecular hallmarks, including changes to haematopoietic stem cells, and is a primary risk factor for chronic diseases. X chromosome inactivation (XCI) randomly transcriptionally silences either the maternal or paternal X in each cell of XX,46 females to balance the gene expression with XY,46 males. Age acquired XCI-skew describes the preferential inactivation of one X chromosome across a tissue, which is particularly prevalent in blood tissues of ageing females and yet its clinical consequences are unknown.Methods We assayed XCI in 1,575 females from the TwinsUK population cohort and employed prospective, cross-sectional, and intra-twin designs to characterise the relationship of XCI-skew with molecular, cellular, and organismal measures of ageing, and cardiovascular disease risk and cancer diagnosis.Results We demonstrate that XCI-skew is independent of traditional markers of biological ageing and is associated with a haematopoietic bias towards the myeloid lineage. Using an atherosclerotic cardiovascular disease risk score, which captures traditional risk factors, XCI-skew is associated with an increased cardiovascular disease risk both cross-sectionally and within XCI-skew discordant twin pairs. In a prospective 10-year follow-up study, XCI-skew is predictive of future cancer incidence.Conclusions Our study demonstrates that age acquired XCI-skew captures changes to the haematopoietic stem cell population and has clinical potential as a unique biomarker of chronic disease risk.Funding KSS acknowledges funding from the Medical Research Council (MR/M004422/1 and MR/R023131/1). JTB acknowledges funding from the ESRC (ES/N000404/1). MM acknowledges funding from the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London. TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd and the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London.Competing Interest StatementCJS is a consultant for Zoe Ltd. All other authors declare they have no competing interests.Funding StatementThis study was funded by the Medical Research Council (MR/M004422/1 and MR/R023131/1) and ESRC (ES/N000404/1)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Committee of St. Thomas Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData on TwinsUK participants are available to bona fide researchers under managed access due to governance and ethical constraints. Raw data should be requested via our website (https://twinsuk.ac.uk/resources-for-researchers/access-our-data/) and requests are reviewed by the TwinsUK Resource Executive Committee (TREC) regularly. https://twinsuk.ac.uk/resources-for-researchers/access-our-data/